Item request has been placed! ×
Item request cannot be made. ×
loading  Processing Request

Haptoglobin phenotype, pre-eclampsia, and response to supplementation with vitamins C and E in pregnant women with type-1 diabetes.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
  • Author(s): Weissgerber TL;Weissgerber TL; Gandley RE; Roberts JM; Patterson CC; Holmes VA; Young IS; McCance DR
  • Source:
    BJOG : an international journal of obstetrics and gynaecology [BJOG] 2013 Sep; Vol. 120 (10), pp. 1192-9. Date of Electronic Publication: 2013 May 30.
  • Publication Type:
    Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • Language:
    English
  • Additional Information
    • Corporate Authors:
    • Source:
      Publisher: Wiley-Blackwell Country of Publication: England NLM ID: 100935741 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1471-0528 (Electronic) Linking ISSN: 14700328 NLM ISO Abbreviation: BJOG Subsets: MEDLINE
    • Publication Information:
      Publication: : Oxford : Wiley-Blackwell
      Original Publication: Oxford [England] : Blackwell Science, [2000]-
    • Subject Terms:
    • Abstract:
      Objective: The phenotype of the antioxidant and pro-angiogenic protein haptoglobin (Hp) predicts cardiovascular disease risk and treatment response to antioxidant vitamins in individuals with diabetes. Our objective was to determine whether Hp phenotype influences pre-eclampsia risk, or the efficacy of vitamins C and E in preventing pre-eclampsia, in women with type-1 diabetes.
      Design: This is a secondary analysis of a randomised controlled trial in which women with diabetes received daily vitamins C and E, or placebo, from 8 to 22 weeks of gestation until delivery.
      Setting: Twenty-five antenatal metabolic clinics across the UK (in north-west England, Scotland, and Northern Ireland).
      Population: Pregnant women with type-1 diabetes.
      Methods: Hp phenotype was determined in white women who completed the study and had plasma samples available (n = 685).
      Main Outcome Measure: Pre-eclampsia.
      Results: Compared with Hp 2-1, Hp 1-1 (OR 0.59, 95% CI 0.30-1.16) and Hp 2-2 (OR 0.93, 95% CI 0.60-1.45) were not associated with significantly decreased pre-eclampsia risk after adjusting for treatment group and HbA1c at randomisation. Our study was not powered to detect an interaction between Hp phenotype and treatment response; however, our preliminary analysis suggests that vitamins C and E did not prevent pre-eclampsia in women of any Hp phenotype (Hp 1-1, OR 0.77, 95% CI 0.22-2.71; Hp 2-1, OR 0.81, 95% CI 0.46-1.43; Hp 2-2, 0.67, 95% CI 0.34-1.33), after adjusting for HbA1c at randomisation.
      Conclusions: The Hp phenotype did not significantly affect pre-eclampsia risk in women with type-1 diabetes.
      (© 2013 RCOG.)
    • References:
      Lancet. 2002 Jun 1;359(9321):1877-90. (PMID: 12057549)
      J Med Genet. 2003 Mar;40(3):214-6. (PMID: 12624142)
      BJOG. 2009 May;116(6):780-8. (PMID: 19432566)
      Am J Obstet Gynecol. 2002 Jul;187(1):127-36. (PMID: 12114900)
      Antioxid Redox Signal. 2007 Mar;9(3):355-66. (PMID: 17184181)
      Am J Obstet Gynecol. 2005 Feb;192(2):520-1. (PMID: 15695996)
      J Am Coll Cardiol. 2002 Dec 4;40(11):1984-90. (PMID: 12475459)
      Diabetes Care. 2004 Dec;27(12):2819-23. (PMID: 15562191)
      Am J Obstet Gynecol. 2012 Apr;206(4):358.e10-8. (PMID: 22340942)
      J Clin Invest. 1993 Mar;91(3):977-85. (PMID: 7680672)
      N Engl J Med. 2006 Apr 27;354(17):1796-806. (PMID: 16641396)
      Arterioscler Thromb Vasc Biol. 2008 Feb;28(2):341-7. (PMID: 18032779)
      Hypertens Pregnancy. 2001;20(1):IX-XIV. (PMID: 12044323)
      Obstet Gynecol. 2007 Dec;110(6):1311-8. (PMID: 18055726)
      Diabetes. 2008 Oct;57(10):2794-800. (PMID: 18599520)
      Lancet. 2010 Jul 24;376(9737):259-66. (PMID: 20580423)
      Clin Chem Lab Med. 2006;44(8):924-8. (PMID: 16879055)
      Clin Chem. 1996 Oct;42(10):1589-600. (PMID: 8855140)
      Diabetes Care. 2009 Nov;32(11):2005-9. (PMID: 19675195)
      Diabetes. 2008 Jun;57(6):1702-6. (PMID: 18332093)
      Diabetes Care. 2004 Apr;27(4):925-30. (PMID: 15047650)
      Antioxid Redox Signal. 2010 Feb;12(2):293-304. (PMID: 19659435)
      J Forensic Sci. 1987 Nov;32(6):1754-74. (PMID: 3480937)
      Lancet. 1999 Sep 4;354(9181):810-6. (PMID: 10485722)
      Diabetes Care. 2004 Nov;27(11):2767. (PMID: 15505023)
      Lancet. 2006 Apr 8;367(9517):1145-54. (PMID: 16616557)
      Arterioscler Thromb Vasc Biol. 2008 Mar;28(3):e18-20. (PMID: 18296583)
      J Am Coll Cardiol. 2011 Mar 22;57(12):1404-23. (PMID: 21388771)
      Atherosclerosis. 2010 Jul;211(1):25-7. (PMID: 20223458)
      J Clin Invest. 2003 Mar;111(5):649-58. (PMID: 12618519)
      Pharmacogenomics. 2010 May;11(5):675-84. (PMID: 20415560)
      N Engl J Med. 2010 Apr 8;362(14):1282-91. (PMID: 20375405)
      Endocrine. 2010 Oct;38(2):303-8. (PMID: 20972727)
      Placenta. 2002 May;23(5):359-72. (PMID: 12061851)
    • Grant Information:
      P01 HD030367 United States HD NICHD NIH HHS; 083145/Z/07/Z United Kingdom WT_ Wellcome Trust; MR/K023241/1 United Kingdom MRC_ Medical Research Council; K12 HD065987 United States HD NICHD NIH HHS; Canada CAPMC CIHR; 067028/Z/02/Z United Kingdom WT_ Wellcome Trust; United Kingdom WT_ Wellcome Trust; K12HD065987 United States HD NICHD NIH HHS
    • Contributed Indexing:
      Investigator: MJ Maresh; D Pearson; J Walker
      Keywords: Haptoglobin phenotype; pre-eclampsia; pregnancy; type-1 diabetes; vitamin C; vitamin E
    • Accession Number:
      0 (Antioxidants)
      0 (Haptoglobins)
      1406-18-4 (Vitamin E)
      PQ6CK8PD0R (Ascorbic Acid)
    • Publication Date:
      Date Created: 20130531 Date Completed: 20131114 Latest Revision: 20211021
    • Publication Date:
      20211220
    • Accession Number:
      PMC3860176
    • Accession Number:
      10.1111/1471-0528.12288
    • Accession Number:
      23718253